Sangamo launches auction for ST-503 pain program as Chapter 11 asset sales close with $163.55 million proceeds
SGMO•Sangamo set a fourth-quarter 2026 auction deadline for its ST-503 chronic neuropathic pain program and said completed asset sales generated $163.55 million in gross cash proceeds.
1. Asset sales close
The court-supervised Section 363 sales included PTC’s $111 million cash purchase of the ST-920 Fabry disease program, with up to $100 million in milestone payments, and Lilly’s $50 million cash acquisition of Sangamo’s capsid delivery, zinc finger and MINT platforms, along with the ST-506 prion disease program. Sangamo used the proceeds to repay all outstanding amounts under its debtor-in-possession financing facility from Future Solutions.
